Clarity’s strong collaboration with Associate Professor Paul Donnelly at the School of Chemistry and Bio21 Institute, University of Melbourne enabled the initial manufacture and development of the product that was then translated into the clinic in the recently completed SARTATE™ proof-of-concept clinical trial for neuroendocrine tumours (NETs).